1月30日中午12點(diǎn)，仁醫(yī)醫(yī)療四人團(tuán)隊(duì)前往哥廷根大學(xué)醫(yī)療中心精神病學(xué)及精神治療科拜訪該科主任Wiltfang教授。精神病學(xué)及精神治療科獨(dú)立辦公，距離醫(yī)療中心總院區(qū)1.3公里，設(shè)有獨(dú)立的實(shí)驗(yàn)樓層，方便該科進(jìn)行科研活動(dòng)。Wiltfang教授攜科研負(fù)責(zé)人Dr. Esselmann親自接待仁醫(yī)醫(yī)療團(tuán)隊(duì)。據(jù)Wiltfang教授介紹，該科為全年齡段的病人提供所有精神病學(xué)診療服務(wù)，共有175張病床，其中110張住院病床，65張日間病床。2019年門診病人約6800人，年均住院病人約2000人。除了診療服務(wù)外，科研是該科日常工作的重點(diǎn)，科研成果及產(chǎn)出在全院64個(gè)臨床科室及研究所中名列前五。得益于哥廷根整座城市的科研氛圍，該科與馬克斯普朗克多學(xué)科神經(jīng)科學(xué)研究所等多個(gè)分所、哥廷根大學(xué)醫(yī)療中心各學(xué)科、德國神經(jīng)退行性疾病中心等科研機(jī)構(gòu)合作進(jìn)行相關(guān)轉(zhuǎn)化研究。Wiltfang教授本人的研究重點(diǎn)在分子/生物精神病學(xué)和非侵入性腦刺激。該科還設(shè)有6個(gè)教授席位，分別是分子精神病學(xué)、神經(jīng)退行性疾病表觀遺傳學(xué)、表觀遺傳學(xué)及基因?qū)W、分子神經(jīng)生物學(xué)、轉(zhuǎn)化神經(jīng)蛋白質(zhì)組學(xué)及法醫(yī)精神病學(xué)。Wiltfang教授還分享，為支持環(huán)保理念及進(jìn)一步加強(qiáng)醫(yī)教研之間的聯(lián)系與合作，哥廷根大學(xué)醫(yī)療中心將投入11億歐元將總院區(qū)進(jìn)行翻新和改造，使其更符合可持續(xù)發(fā)展理念。隨后Wiltfang教授及Dr. Esselmann帶我們參觀了會(huì)議室、科室主要診療區(qū)域及各實(shí)驗(yàn)室。多年來Wiltfang教授及其團(tuán)隊(duì)一直致力于開發(fā)阿爾茨海默癥生物標(biāo)志物引導(dǎo)的早期診斷，其團(tuán)隊(duì)已開發(fā)了一個(gè)全新的診斷系統(tǒng)-A β-兩步免疫分析法，只需要通過血液化驗(yàn)，可以在早期臨床前階段，甚至是病人出現(xiàn)臨床癥狀15年之前，對(duì)初期的阿爾茨海默病性癡呆進(jìn)行精確鑒別，這為在全球范圍內(nèi)制定最有效的預(yù)防性治療策略創(chuàng)造了可能性。Wiltfang教授將攜手仁醫(yī)醫(yī)療及中國三甲醫(yī)院，建立基于血液的高通量阿爾茨海默癥早期診斷系統(tǒng)，對(duì)高?；颊哌M(jìn)行早期篩查，并以藥物或生活方式改善進(jìn)行早期干預(yù)以延緩疾病發(fā)展。

At noon on January 30th, Gloryren’s team of four went to the Department of Psychiatry and Psychotherapy at the University Medical Center G?ttingen to visit Prof. Wiltfang, the Director of the department. The Department of Psychiatry and Psychotherapy functions alone in its own building, which is 1.3 kilometers from the Medical Center. It enjoys graceful surroundings, providing pleasant environment for both outpatient and inpatient. The department also has a whole floor for scientific research use exclusively. Prof. Wiltfang, together with the head of research, Dr. Esselmann welcomed our team from Gloryren. Prof. Wiltfang introduced that the Department of Psychiatry and Psychotherapy provides all psychiatric diagnostic and treatment services to patients of all ages. It holds 175 beds, including 110 inpatient beds and 65 beds for day clinic patients. In 2019, the department received about 6,800 clinic patients, with about 2000 inpatients annually. In addition to medical services, scientific research is the focus of the department’s daily work. Its scientific research results and output are among the top five of 64 clinics, departments, and pre-clinical research institutes. Benefiting from the scientific research atmosphere of the whole city of G?ttingen, the department has cooperation for translational research with multiple scientific research institutions such as Max Planck Institute for Multidisciplinary Neuroscience and other branches, other specialties of the University Medical Center G?ttingen, and German Center for Neurodegenerative Diseases G?ttingen. The focus of the research of Prof. Wiltfang lies in molecular/biological psychiatry and non-invasive brain stimulation.The Department of Psychiatry and Psychotherapy also has six more professors, and they respectively focus on Molecular Psychiatry, Epigenetics of Neurodegenerative Diseases, Epigenetics and Genetics, Molecular Neurobiology, Translational Neuroproteomics, and Forensic Psychiatry & Psychotherapy. Prof. Wiltfang also told us that to support the environmental-friendly idea and to facilitate close connections and cooperation between healthcare, teaching, and research, the University Medical Center G?ttingen will invest 1.1 billion euros for renovating and transforming its central hospital, making it more consistent with the concept of sustainable development. Later, Prof. Wiltfang and Dr. Esselmann showed us around the meeting room, the main diagnosis and treatment areas, and the laboratories. For many years, Prof. Wiltfang and his team have dedicated themselves to developing biomarker-guided early diagnostics of Alzheimer's dementia, and they’ve developed a brand new system, namely the Aβ-2step-Immunoassay, which can accurately identify early stage Alzheimer's disease dementia in preclinical stages, even 15 years before the patient develops clinical symptoms, using only blood tests. This is the dawn of developing the most efficient preventive strategies worldwide. In the coming future, Prof. Wiltfang will join hand in hand with Gloryren and Grade Three Class A hospitals in China to build a high-performance early diagnostics system for Alzheimer's dementia based on blood assays. This system will allow early screening of high-risk patients and early intervention with medications or lifestyle changes to slow disease progression.